Login to Your Account



Flawed Design for Pivotal Crohn's Study Sinks Osiris

By Jennifer Boggs


Monday, March 30, 2009
Shares of Osiris Therapeutics Inc. sank 21 percent after the firm reported problems with the design of an ongoing pivotal Phase III study of adult stem cell product Prochymal in Crohn's disease and halted the study only 60 patients away from the 270-subject enrollment goal. (BioWorld Today)

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription